Istodax (romidepsin) / Astellas, BMS 
Welcome,         Profile    Billing    Logout  
 310 Diseases   23 Trials   23 Trials   1465 News 


12345678910111213...2021»
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Inhibition of MICA and MICB shedding with a GAALIE mutant antibody promotes robust natural killer cells' anti-leukemia functions (Exhibit Hall F1; Poster Board Number: B805) -  Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_2204;    
    Notably, when combined with a histone deacethylase inhibitor (romidepsin) that induces MICB mRNA expression, 7C6-GAALIE induces greater levels of ADCC and interferon-gamma production by NK cells against human acute myeloid leukemia (AML) cell lines...Finally, in a mouse AML model in Fc receptor-humanized mice, 7C6-GAALIE lowers to nearly undetectable levels the leukemia burden in the perypheral blood. Collectively, the GAALIE mutations optimizes the anti-leukemia activity of this anti-MICA/B antibody to potently promotes immunity against AML.
  • ||||||||||  trichostatin A (VTR-297) / Vanda, Istodax (romidepsin) / Astellas, BMS
    Preclinical, Journal:  Epigenetic small-molecule screen for inhibition and reversal of acinar ductal metaplasia in mouse pancreatic organoids. (Pubmed Central) -  Mar 21, 2024   
    Collectively, in cryptosporidiosis, romidepsin succeeded in enhancing pyroptosis in the oocysts and infected epithelium, reducing infection and shifting the brush border towards normalisation. We developed a novel morphology-based screen using organoids from wildtype and p48Cre/+ (Cre) mice to discover epigenetic modulators that inhibit or reverse pancreatic ADM more effectively than the broad-spectrum HDAC inhibitor trichostatin A (TSA)...The class I HDAC inhibitors apicidin and FK228, and the histone methyltransferase inhibitor chaetocin demonstrated pronounced ADM inhibition and reversal without inducing significant cytotoxicity at 1
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Istodax (romidepsin) / Astellas, BMS
    Preclinical, Journal, Epigenetic controller:  Systemic histone deacetylase inhibition ameliorates the aberrant responses to acute stress in socially isolated male mice. (Pubmed Central) -  Mar 19, 2024   
    Treatment with class I histone deacetylase (HDAC) inhibitors ameliorates the aggressive behaviour and social interaction deficits of SIRS males, and normalizes glutamatergic currents in PFC neurons. It provides an epigenetic mechanism and intervention avenue for aberrant stress responses induced by chronic social isolation.
  • ||||||||||  Isentress (raltegravir) / Merck (MSD), Istodax (romidepsin) / Astellas, BMS
    Effective Elimination of HIV-1 Infected CD4+ T-Cells by NKG2C+ 'Memory-Like' NK Mediated by Trail (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_1056;    
    Finally, impact of anti-TRAIL, anti-NKG2C and anti-NKG2D or isotypic mAbs in NK cell-mediated elimination of p24+ HIV-1 infected CD4+ T cells from PLWH was tested in the presence of Romidepsin and Raltegravir.CD56dim and CD56- CD16+ NK cells from PLWH exposed to nano-PIC DC displayed increased levels of TRAIL compared to cells stimulated with control nano DC (p=0.0039). In conclusion, cytotoxic function of memory-like NKG2C+ CD57- NK cells associated with good functional elimination of HIV-1 reservoir CD4+ T cells is mediated by TRAIL.
  • ||||||||||  ingenol-B stabilized (GSK445A) / GSK, Istodax (romidepsin) / Astellas, BMS
    Different Impact of Latency Reversal in Cells From People With HIV Viremia and With ART Suppression (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_1021;    
    In conclusion, cytotoxic function of memory-like NKG2C+ CD57- NK cells associated with good functional elimination of HIV-1 reservoir CD4+ T cells is mediated by TRAIL. Here, we compared the effect of the ingenol-based PKC agonist GSK445A alone or in combination with the HDACi romidepsin (RMD) on HIV transcription in cells from viremic and virally suppressed individuals.We measured the effect GSK445A +/- RMD on HIV transcription in CD4+ T cells isolated from the blood of 10 PWH on ART with undetectable plasma viral load as well as in 18 untreated individuals (median = 3.31
  • ||||||||||  Trogarzo (ibalizumab IV) / Theratechnologies, TaiMed Biologics, AZD5582 / AstraZeneca, Istodax (romidepsin) / Astellas, BMS
    CD4-Targeted mRNA Delivery of Tat Reverses HIV-1 Latency () -  Mar 16, 2024 - Abstract #CROI2024CROI_1010;    
    Ibalizumab (anti-CD4) was conjugated to mRNA-LNPs to generate CD4-targeted mRNA-LNPs...CD4-targeted Tat mRNA-LNPs selectively drive viral gene expression without cytotoxicity. These findings show that viral transcriptional programs, such as latency, can be modified using cell-targeted mRNA gene therapy.
  • ||||||||||  LOW DOSE DOUBLE EPIGENETIC THERAPY IMPROVES IMMUNOTHERAPY RESPONSE AND PROLONGS SURVIVAL IN PANCREATIC CANCER. (103AB - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_2386;    
    We previously showed, using the KPC (Kras LSL G12D/+; p53 r172H/+; Pdx1-Cre) mouse model of pancreatic cancer (PDAC), that sequential treatment with the DNA hypomethylating agent (HMA) decitabine (DAC) followed by aPD-1 initially enhanced anti-tumor effects, yet tumors developed resistance linked to a unique M2-polarized Chil3+ myeloid subtype...We then evaluated four different HDAC inhibitors with reported immunomodulatory effects and non-overlapping HDAC isoform specificities: Romidepsin (RM), Domatinostat (DM), Pracinostat (PR) and Entinostat (EN)...Our findings identify a functionally immune suppressive HMA specific myeloid effect. The addition of a second epigenetic agent enhances the therapeutic efficacy resulting in prolonged survival and reverses the suppressive myeloid cell related effects of DAC + aPD1.
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    The histone deacetylase inhibitor romidepsin is a potential therapeutic for metastatic osteosarcoma (Section 43) -  Mar 5, 2024 - Abstract #AACR2024AACR_9259;    
    Using a tail vein injection model of osteosarcoma lung metastases, romidepsin dose dependently prolonged survival and reduced the area and number of lung metastases in immunodeficient mice injected with 143B cells and a syngeneic model using K7M2 cells. Romidepsin will be evaluated in mice with metastases from patient-derived cells and if effective, will be repurposed for canine and human clinical trials to improve outcomes in metastatic osteosarcoma without the associated costs and extensive timeframe of traditional drug discovery.
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Preclinical development of a novel Romidepsin nanoparticle for the treatment of T-Cell lymphoid malignancies (Section 23) -  Mar 5, 2024 - Abstract #AACR2024AACR_5335;    
    We anticipate that the improved activity and tolerability of NanoRomi relate to the altered pharmacologic profile and superior bioavailability of the drug, which optimizes the effects of the drug for its influence on epigenetic biology. This unique platform offers the prospect of improving the tolerability and efficacy of epigenetic treatment strategies in these challenging diseases.
  • ||||||||||  Farydak (panobinostat) / Secura Bio, Istodax (romidepsin) / Astellas, BMS
    Common T-Cell Features Predicting Time to Rebound in Interventional and Non-Interventional Treatment () -  Mar 5, 2024 - Abstract #CROI2024CROI_148;    
    CD8+ T cells expressing high levels of BIRC5 and low levels of CD29 predict longer time-to-rebound in both interventional and non-interventional ATI cohorts. These 'pro-survival' CD8+ T cells may be better able to survive during the early post-ART period and thereby slow down viral rebound upon ATI.
  • ||||||||||  Farydak (panobinostat) / Secura Bio, AZD5582 / AstraZeneca, Istodax (romidepsin) / Astellas, BMS
    HIV Infection and Reactivation Heterogeneity in Tonsillar and Intestinal Models of HIV Persistence (Poster hall) -  Mar 5, 2024 - Abstract #CROI2024CROI_144;    
    In our tonsillar and intestinal tissue models of HIV persistence, CD4+ T cell populations exhibited varying susceptibility to viral infection and reactivation, showing significant differences between tissues. Further research is required to identify LRAs effective against distinct HIV cellular reservoirs within these tissues.
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Journal:  A GSH-resistant FK228 analogue containing a stable disulfide bond. (Pubmed Central) -  Feb 19, 2024   
    Specifically, the d-Cys in FK228 was replaced by d-Pen, the total synthetic pathway was optimized, and the novel synthetic FK228 analogue (FK-P) stability was verified. FK-P can also be used as a new drug molecule in the future to participate in the research of related biological mechanisms or the treatment of diseases.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance. (Pubmed Central) -  Jan 23, 2024   
    Pharmacological screening identified romidepsin, YM155, apitolisib, NVP-TAE684 and dasatinib as potential antitumor agents in lenvatinib-resistant PDC and PDO models...A combination of romidepsin and immunotherapy achieved robust and synergistic antitumor effects against lenvatinib resistance in humanized immunocompetent PDX models. Collectively, our findings suggest that patient-derived liver cancer models effectively recapitulate lenvatinib resistance observed in clinical settings and expedite drug discovery for advanced liver cancer, providing a feasible multidimensional platform for personalized medicine.
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Preclinical, Journal:  Establishment and functional testing of a novel ex vivo extraskeletal osteosarcoma cell model (USZ20-ESOS1). (Pubmed Central) -  Jan 4, 2024   
    Through a functional screening approach, we were able to identify novel individual anti-cancer drug sensitivities for different drugs such as romidepsin, miverbresib and to multiple kinase inhibitors. Overall, our new ESOS ex vivo cell model represents a valuable tool for investigating disease mechanisms and answering basic and translational research questions.
  • ||||||||||  Journal, Epigenetic controller:  The methyltransferases METTL7A and METTL7B confer resistance to thiol-based histone deacetylase inhibitors. (Pubmed Central) -  Dec 28, 2023   
    RNA sequencing analysis revealed upregulation of the mRNA coding for the putative methyltransferase, METTL7A, whose paralog, METTL7B, was previously shown to methylate thiol groups on hydrogen sulfide and captopril...We demonstrate that expression of METTL7A or METTL7B confers resistance to thiol-based HDACis and that both enzymes are capable of methylating thiol-containing HDACis. We thus propose that METTL7A and METTL7B confer resistance to thiol-based HDACis by methylating and inactivating the zinc-binding thiol.
  • ||||||||||  Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Istodax (romidepsin) / Astellas, BMS
    Journal, Epigenetic controller:  Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy. (Pubmed Central) -  Dec 21, 2023   
    Together, these results indicate that the histone deacetylase inhibitor romidepsin can improve the efficacy of salvage therapies for relapsed TP53-mutated leukemia. Since romidepsin has been approved for clinical use in some adult malignancies, these findings may be rapidly translated to clinical practice.
  • ||||||||||  Beleodaq (belinostat) / Aurobindo, Spectrum Pharma, Istodax (romidepsin) / Astellas, BMS
    GATA-3 Dependent Gene Transcription Is Impaired upon HDAC Inhibition (SDCC - Halls G-H) -  Nov 3, 2023 - Abstract #ASH2023ASH_5795;    
    Our findings indicate that epigenetic targeting of the GATA2/3-FOXA1-HER3 axis may be an effective therapeutic strategy for the eradication of BLBC tumors. Among the 5,510-6,811 transcripts that were differentially expressed upon either belinostat or romidepsin treatment, respectively,
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Journal:  Identification of the lipodepsipeptide selethramide encoded in a giant nonribosomal peptide synthetase from a Burkholderia bacterium. (Pubmed Central) -  Oct 13, 2023   
    Metabolomics studies showed that FERM BP-3421 also produces antifungal aminopyrrolnitrin and approved anticancer romidepsin...Mutants defective in selethramide biosynthesis showed reduced surfactant activity and impaired swarming motility that could be chemically complemented with selethramide. This work unveils a lipopeptide that promotes surface motility, establishes improved DNA transfer efficiency, and sets the stage for continued natural product identification from a prolific strain.